TY - JOUR
T1 - Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer
T2 - A systematic review and pooled analysis
AU - Chebib, Ralph
AU - Verlingue, Loic
AU - Cozic, Nathalie
AU - Faron, Matthieu
AU - Burtin, Pascal
AU - Boige, Valérie
AU - Hollebecque, Antoine
AU - Malka, David
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.
AB - The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.
KW - Angiogenesis inhibitors
KW - Colorectal cancer
KW - Pooled analysis
KW - Second-line chemotherapy
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85028073533&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2017.07.004
DO - 10.1053/j.seminoncol.2017.07.004
M3 - Review article
C2 - 28923209
AN - SCOPUS:85028073533
SN - 0093-7754
VL - 44
SP - 114
EP - 128
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 2
ER -